Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F. Maffioli M, et al. Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. Blood Adv. 2019. PMID: 31698448 Free PMC article.
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A. Passamonti F, et al. Among authors: maffioli m. Blood. 2010 Mar 4;115(9):1703-8. doi: 10.1182/blood-2009-09-245837. Epub 2009 Dec 14. Blood. 2010. PMID: 20008785 Free article.
EZH2 mutational status predicts poor survival in myelofibrosis.
Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM. Guglielmelli P, et al. Among authors: maffioli m. Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14. Blood. 2011. PMID: 21921040 Free article.
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A. Passamonti F, et al. Among authors: maffioli m. Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26. Blood. 2012. PMID: 22740446 Free article.
Clinical predictors of outcome in MPN.
Passamonti F, Maffioli M, Merli M, Ferrario A, Caramazza D. Passamonti F, et al. Among authors: maffioli m. Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28. Hematol Oncol Clin North Am. 2012. PMID: 23009940 Review.
Novel agents in indolent lymphomas.
Merli M, Ferrario A, Basilico C, Maffioli M, Caramazza D, Appio L, Arcaini L, Passamonti F. Merli M, et al. Among authors: maffioli m. Ther Adv Hematol. 2013 Apr;4(2):133-48. doi: 10.1177/2040620712466865. Ther Adv Hematol. 2013. PMID: 23610620 Free PMC article.
Looking for CALR mutations in familial myeloproliferative neoplasms.
Maffioli M, Genoni A, Caramazza D, Mora B, Bussini A, Merli M, Giorgino T, Casalone R, Passamonti F. Maffioli M, et al. Leukemia. 2014 Jun;28(6):1357-60. doi: 10.1038/leu.2014.33. Epub 2014 Jan 20. Leukemia. 2014. PMID: 24441291 No abstract available.
91 results